Tolvaptan, hyponatremia, and heart failure

References

• GhaliJKMechanisms, risks, and new treatment options for hyponatremiaCardiology200811114715718434717
   PubMed Web of Science ®Google Scholar
• RenneboogBVendemergelXMantoMNMild chronic hyponatremia is associated with falls, unsteadiness and attention deficitsAm J Med200611971e171e816431193
   PubMedGoogle Scholar
• SandhuHSGillesEDeVitaMVHyponatremia associated with large bone fracture in elderly patientsInt Urol Nephrol20094173373719472069
   PubMed Web of Science ®Google Scholar
• KinsellSMoranSSullivanMOHyponatremia independent of osteoporosis is associated with fracture occurrenceClin J Am Soc Nephrol2010527528020056759
   PubMed Web of Science ®Google Scholar
• Gankam KengneFAndresCSattarLMild hyponatremia and risk of fracture in the ambulatory elderlyQJM200810158358818477645
   PubMed Web of Science ®Google Scholar
• WaikarSSMountDBCurhanGCMortality after hospitalization with mild, moderate, and severe hyponatremiaAm J Med200912285786519699382
   PubMed Web of Science ®Google Scholar
• WaldRJaberBLPriceLLUpadhyayAMadiasNEImpact of hospital-associated hyponatremia on selected outcomesArch Intern Med201017029430220142578
   PubMed Web of Science ®Google Scholar
• SajadiehABiniciZMouridsenMRMild hyponatremia carries a poor prognosis in community subjectsAm J Med200912267968619559171
   PubMed Web of Science ®Google Scholar
• GheorghiadeMAbrahamWTAlbertNMRelationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Optimize-HF Investigators and CoordinatorsEur Heart J20072898098817309900
   PubMed Web of Science ®Google Scholar
• GhaliJKHyponatremia in heart failure: a call for redefinitionEur Heart J20072892092117430999
   PubMed Web of Science ®Google Scholar
• DecauxGIs asymptomatic hyponatremia really asymptomatic?Am J Med20061197AS79S8216843090
   PubMed Web of Science ®Google Scholar
• GuytonACThe body fluids and kidneysGuytonACHallJETextbook of Medical PhysiologyPhiladelphia (PA)WB Saunders Company2006291414
   Google Scholar
• OlietSHBourqueCWMechanosensitive channels transducer osmosensitivity in supraoptic neuronsNature19933643413437687327
   PubMed Web of Science ®Google Scholar
• WadeCEKeilLCRamsayDJRole of volume and osmolality in the control of plasma vasopressin in dehydrated dogsNeuroendocrinology1983373493536358935
   PubMed Web of Science ®Google Scholar
• SchrierRWWater and sodium retention in edematous disorder: role of vasopressin and aldosteroneAm J Med2006119S47S5316843085
   PubMed Web of Science ®Google Scholar
• SchrierRWBerlTAndersonRJOsmotic and nonosmotic control of vasopressin releaseAm J Physiol1979236F321F332373467
   PubMed Web of Science ®Google Scholar
• MitchellLDBarronKBrodyMJTwo possible actions for circulating angiotensin II in the control of vasopressin releasePeptides198235035077122277
   PubMed Web of Science ®Google Scholar
• ThibonnierMConartyDMPrestonJAMolecular pharmacology of human vasopressin receptorsAdv Exp Med Biol199844925127610026814
   PubMed Web of Science ®Google Scholar
• AliFGuglinMVaitkeviciusPTherapeutic potential of vasopressin receptor antagonistsDrugs20076784785817428103
   PubMed Web of Science ®Google Scholar
• NielsenSKwonTHChristensenBMPhysiology and pathophysiology of renal aquaporinsJ Am Soc Nephrol19991064766310073616
   PubMed Web of Science ®Google Scholar
• TanoueAItoSHondaKThe vasopressin V1B receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditionsJ Clin Invest200411330230914722621
   PubMed Web of Science ®Google Scholar
• Samsca (tolvaptan) [prescribing Information]Tokyo, JapanOtsuka Pharmaceutical Co, Ltd2009 http://www.samsca.com/pdf/samscaPI.pdf. Accessed May 2, 2010.
   Google Scholar
• YamamuraYNakamuraSItohSOPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in ratsJ Pharmacol Exp Ther19982878608679864265
   PubMed Web of Science ®Google Scholar
• ShoafSEWangZBricmontPPharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjectsJ Clin Pharmacol2007471498150717925589
   PubMed Web of Science ®Google Scholar
• HauptmanPJZimmerCUdelsonJComparison of two doses and dosing regimens of tolvaptan in congestive heart failureJ Cardiovasc Pharmacol20054660961416220067
   PubMed Web of Science ®Google Scholar
• HiranoTYamamuraYNakamuraSEffects of the V2 receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in ratsJ Pharmacol Exp Ther200029228829410604960
   PubMed Web of Science ®Google Scholar
• ShoafSEMallikaarjunSEffect of ketoconazole and grapefruit juice, CYP3A4 inhibitors, on the pharmacokinetics of tolvaptan, a non-peptide vasopressin antagonistClin Pharmacol Ther200883S57
   Web of Science ®Google Scholar
• MallikaarjunSEffect of rifampin, CYP3A4 inducer, on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide vasopressin antagonistClin Pharmacol Ther200883S57
   Web of Science ®Google Scholar
• ShoafSEElizariMVWangZTolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmiasJ Cardiovasc Pharmacol Ther20051016517116211205
   PubMed Web of Science ®Google Scholar
• ShoafSEBramerSLBricmontPPharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazideJ Cardiovasc Pharmacol20075021322217703139
   PubMed Web of Science ®Google Scholar
• ShoafSEWangZMallikaarjunSLack of clinically significant interaction between steady state tolvaptan and digoxin in healthy volunteersClin Pharmacol Ther200475P37
   Web of Science ®Google Scholar
• KonstamMAGheorghiadeMBurnettJCEffects of oral tolvaptan in patients hospitalized for worsening heart failure, the EVEREST outcome trialJAMA20072971319133117384437
   PubMed Web of Science ®Google Scholar
• OkitaKSakaidaIOkadaMA multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosisJ Gastroenterol20104597998720387081
   PubMed Web of Science ®Google Scholar
• GheorghiadeMGottliebSSUdelsonJEVasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremiaAm J Cardiol200671064106716563917
   PubMed Web of Science ®Google Scholar
• SchrierRWGrossPGheorghiadeMTolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremiaN Engl J Med20063552099211217105757
   PubMed Web of Science ®Google Scholar
• BerlTQuittnat-PelletierFVerbalisJOral tolvaptan is safe and effective in chronic hyponatremiaJ Am Soc Nephrol20102170571220185637
   PubMed Web of Science ®Google Scholar
• JosiassenRCGoldmanMJessaniMDouble-blind, placebo-controlled, multicenter trial of a vasopressin V2 receptor antagonist in patients with schizophrenia and hyponatremiaBiol Psychiatry2008641097100018692175
   PubMed Web of Science ®Google Scholar
• GheorghiadeMNiaziIOuyangJVasopressin V2 receptor blockade with tolvaptan in patients with chronic heart failure, results from a double-blind, randomized trialCirculation20031072690269612742979
   PubMed Web of Science ®Google Scholar
• GheorghiadeMGattisWABarbagelataARationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failureAm Heart J2003145S51S5412594452
   PubMed Web of Science ®Google Scholar
• GheorghiadeMGattisWAO’ConnorCEffects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trialJAMA20042911963197115113814
   PubMed Web of Science ®Google Scholar
• GheorghiadeMOrlandiVBurnettJCRationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST)J Card Fail20051126026915880334
   PubMed Web of Science ®Google Scholar
• GheorghiadeMKonstamMABurnettJCShort-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure, the EVEREST clinical status trialsJAMA20072971332134317384438
   PubMed Web of Science ®Google Scholar
• PangPSKonstamMAKrasaHBEffects of tolvaptan on dyspnoea relief from the EVEREST trialsEur Heart J2009302233224019561338
   PubMed Web of Science ®Google Scholar
• UdelsonJEOrlandiCOuyangJAcute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trialJACC2008521540154519007589
   PubMedGoogle Scholar
• UdelsonJEMcGrewFAFloresEMulticenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunctionJACC2007492151215917543634
   PubMedGoogle Scholar
• Costello-BoerrigterLCSmithWBBoerrigterGVasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failureAm J Physiol Renal Physiol2006290F273F27816189291
   PubMed Web of Science ®Google Scholar